MEMY Memory Pharmaceuticals Corp (MM)

MONTVALE, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that six abstracts related to its clinical and preclinical programs have been accepted for poster presentations at the 38th Annual Meeting of the Society for Neuroscience in Washington, D.C. from November 15-19, 2008. The abstracts include additional preclinical data for R3487/MEM 3454, the Company's lead nicotinic alpha-7 receptor agonist currently in Phase 2 development for both Alzheimer's disease and cognitive impairment associated the schizophrenia (CIAS), new preclinical data for the Company's lead 5-HT(6) receptor antagonist, MEM 68626, and data from its collaboration with Amgen focused on the development of PDE10 inhibitors. "We continue to advance the development of novel therapies for the treatment of cognitive disorders and look forward to reporting on the new data emerging from our key programs," stated David A. Lowe, Ph.D., Chief Scientific Officer of Memory Pharmaceuticals. "We and our partner Roche are evaluating R3487/MEM 3454 as a treatment for both Alzheimer's disease and CIAS, and the preclinical data for R3487/MEM 3454 adds to the growing body of evidence suggesting the compound enhances cognition. In addition, MEM 68626 continues to demonstrate efficacy in multiple models of memory, including new findings of enhanced performance in a spatial working memory task. Furthermore, we continue to progress our program focused on advancing PDE10 inhibitors for potential clinical development." The following abstracts from Company scientists and collaborators were accepted for poster presentations at the meeting: -- "The alpha-7 receptor partial agonist MEM 3454 increases dopamine and acetylcholine efflux in rat medial prefrontal cortex and hippocampus, alone and augments the effect of atypical antipsychotic drugs" Poster Session 874 Wednesday, November 19, 2008 1:00 p.m. - 5:00 p.m. EST -- "Serotonin 5-HT(6) receptor antagonists modulate episodic, spatial and working memory, highlighting a potential therapeutic role in alleviating deficits associated with mild cognitive impairment and Alzheimer's disease" Poster Session 685 Tuesday, November 18, 2008 1:00 p.m. - 5:00 p.m. EST -- "Identification and characterization of a novel small molecule inhibitor for phosphodiesterase 10A as a potential PET-tracer using LC-MS/MS" Poster Session 885 Wednesday, November 19, 2008 1:00 p.m. - 5:00 p.m. EST -- "Camk2(alpha) Heterozygous knock-out mice: a model of bipolar disorder-related mania" Poster Session 157 Sunday, November 16, 2008 8:00 a.m. - 12:00 p.m. EST -- "Age and task dependent alterations in cognitive performance exist in the rTg4510 mouse model of human tauopathy" Poster Session 439 Monday, November 17, 2008 1:00 p.m. - 5:00 p.m. EST -- "Behavioral characterization of rTg4510 tau transgenic mice" Poster Session 439 Monday, November 17, 2008 1:00 p.m. - 5:00 p.m. EST About the Company Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com/. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain listing on the Nasdaq Capital Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. DATASOURCE: Memory Pharmaceuticals Corp. CONTACT: Jzaneen Lalani, General Counsel, +1-201-802-7249 Web Site: http://www.memorypharma.com/

Copyright